Teva Pharmaceuticals has agreed to pay $35 million to resolve claims it engaged in antitrust behavior to keep its QVAR asthma medications from facing generic competition.
The QVAR class action settlement benefits consumers and entities who purchased or reimbursed some or all of the purchase price for QVAR or QVAR Redihaler products between Jan. 1, 2015, and July 31, 2025.
States included in the QVAR settlement are: Alaska, Arizona, Arkansas, California, Connecticut, Delaware, the District of Columbia, Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
QVAR and QVAR Redihaler are brand-name asthma medications manufactured by Teva Pharmaceuticals. The medication is a corticosteroid that helps prevent asthma attacks.
The class action lawsuit resolved by this settlement claimed Teva Pharmaceuticals violated antitrust laws by preventing generic versions of QVAR from being sold to consumers. The company allegedly took several steps to keep its medication from facing generic competition, including product hops, sham litigation, improper patent listings and reverse payments.
As a result of these alleged actions, consumers claim they paid a higher price for QVAR products, such as Redihaler, than they would have in a competitive market.
Teva has not admitted any wrongdoing but agreed to a $35 million class action settlement to resolve these allegations.
Under the terms of the QVAR settlement, class members can receive a cash payment based on the amount they paid for QVAR products.
Class members who have proof of purchase for QVAR products can receive a larger share of the net settlement fund. Class members without proof of purchase will receive a smaller share of the net settlement fund.
The deadline for exclusion and objection is June 15, 2026.
The final approval hearing for the QVAR settlement is scheduled for Aug. 05, 2026.
To receive a settlement payment, class members must submit a valid claim form by July 31, 2026.
Who’s Eligible
The QVAR class action settlement benefits consumers and entities who purchased or reimbursed some or all of the purchase price for QVAR or QVAR Redihaler products between Jan. 1, 2015, and July 31, 2025, in Alaska, Arizona, Arkansas, California, Connecticut, Delaware, the District of Columbia, Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
Potential Award
Varies
Proof of Purchase
Documentation can include receipts, invoices, pharmacy statements or records, or insurance statements with explanations of benefits.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
07/31/2026
Case Name
Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., Case No. 1:23-cv-11131-NMG, in the U.S. District Court for the District of Massachusetts
Final Hearing
08/05/2026
Settlement Website
Claims Administrator
QVAR Antitrust Settlement
c/o A.B. Data Ltd.
P.O. Box 173034
Milwaukee, WI 53217
[email protected]
866-588-8524
Class Counsel
Todd A. Seaver
BERMAN TABACCO
Joseph M. Vanek
SPERLING KENNY NACHWALTER LLC
Steve D. Shadowen
HILLIARD & SHADOWEN LLP
Thomas M. Sobol
Gregory T. Arnold
HAGENS BERMAN SOBOL SHAPIRO LLP
Defense Counsel
Devora W. Allon
KIRKLAND & ELLIS LLP
Read About More Class Action Lawsuits & Class Action Settlements:
- $60.5M Tinder Plus and Gold discrimination class action settlement
- $2.6M Freedom Energy Oklahoma earthquake class action settlement
- $2.39M Union Bank and Trust data breach class action settlement
- $5M European Wax Center privacy class action settlement
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2026 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
